The 2025 483 pattern for bioanalytical: ISR, reagent-lot, partial validation.

FDA inspections of bioanalytical operations through 2025 produced a tight cluster of observations. Nearly four out of every five 483 line items in the bioanalytical category fall into one of four patterns. Each pattern has a known root cause. Each pattern has a known mitigation. The fact that the cluster is so tight is what makes the pattern teachable — it is also what makes it embarrassing for sponsors when it appears in their own observation history.

/ 01ISR sample-selection randomisation — 28%.

Incurred sample reanalysis became inspection-mandatory after Crystal City IV (2007) and was codified in FDA's 2018 BMV Guidance, EMA's 2011 Guideline, and ICH M10 Section 5. The procedure: 7% of samples for small molecules, 10% for ligand-binding assays, with two-thirds expected to fall within ±20% of the original result (±30% for LBA). The compliance question is not whether ISR was done. It is how the samples were selected.

The top 2025 finding is documentation of randomisation procedure. "Samples were randomly selected" is not a procedure; it is a claim about a procedure. The procedure that satisfies inspection: a documented, reproducible selection algorithm that demonstrably covers the concentration range (high, mid, low), pivotal time points (Cmax window, terminal phase), and demographic distribution where applicable. The procedure is operationalised as an SOP with specific selection rules and an attribution log showing which samples were selected per the rules.

The simple mitigation: write the selection SOP, run it forward through the next study, retain the selection log alongside the ISR result table. Cost: low. Inspection consequence of not doing it: high.

/ 02Reagent-lot bridging documentation — 22%.

Reagent lot changes — antibody, internal standard, working solution, calibrator — happen continuously across a long study or programme. ICH M10 Section 6 expects partial revalidation when a critical reagent changes. The compliance question is what counts as critical, and what bridging study demonstrates equivalence. The 2025 finding pattern shows that sponsors are running the bridging studies but not documenting them in a way that an inspector can reconstruct.

The pattern that fails: reagent-lot change recorded in the LIMS, bridging study performed informally, results filed in a study folder, no signed cross-reference linking the new lot to the validated method. The pattern that passes: a documented bridging protocol pre-specified, reagent-lot certificate of analysis attached, bridging samples spanning the assay range, acceptance criteria pre-defined, signed report linking the new lot to the method's validation history. The discipline mirrors the partial-validation framework, applied to reagents specifically.

Reagent-lot bridging is projected to displace ISR as the #1 483 category by 2028. The CRO infrastructure for ISR is now mature; for reagent-lot bridging it is not.

/ 03Partial-validation pre-definition SOP gaps — 17%.

EMA was strict on partial-validation pre-definition from the 2011 Guideline forward; FDA more permissive. ICH M10 Section 6 inherits the EMA framing. The 2025 finding is that sponsors and CROs do not have an SOP that pre-specifies which changes trigger partial validation, what the partial-validation scope includes per change category, and what acceptance criteria apply. When a change occurs and the partial validation runs, the inspector reads the report against an SOP that the laboratory does not have — and the gap appears as the observation.

What the SOP should name.

Change categories at minimum: critical reagent (antibody, IS), instrument generation, software version material to integration, sample matrix change, analytical column chemistry, sample preparation procedure. For each, the partial-validation scope (selectivity, accuracy, precision, recovery, matrix effect, stability — full or subset). For each, the acceptance criteria. The SOP becomes the contract between the laboratory and inspection, and the partial-validation reports become the executions of the contract.

The SOP is the inspection's reference document. If the SOP does not pre-specify it, the inspection is reading the report against nothing — and "nothing" is not a passing comparison.

/ 04Method-transfer documentation — 14%.

Method transfer between laboratories — sponsor to CRO, CRO to CRO, CRO across geography — invokes ICH M10 Section 6 partial validation. The 2025 finding pattern: the receiving laboratory ran the partial validation and demonstrated competence, but the method-transfer report does not document the receiving laboratory's training, the proficiency study before live samples, the comparison to the originating laboratory's reference data, or the change-control alignment between the two laboratories' SOPs.

The pattern that passes: a method-transfer protocol pre-specifies the proficiency criteria, the cross-laboratory comparison study, the SOP alignment review, the personnel training record, and the post-transfer monitoring period. The transfer report executes the protocol and links every element back. This is straightforward when planned upfront and difficult to reconstruct after the fact.

/ 05The structural reading.

The four findings cluster around documentation of pre-defined procedure. Not absence of procedure — absence of the document that specifies the procedure before it runs, against which the running can be evaluated. ALCOA+ "contemporaneous" requires that the documentation be made at the time of the activity. The pattern that fails 2025 inspections is documentation made in retrospect, often well, often substantively complete, but not contemporaneous to a pre-existing SOP that an inspector can use as the reference.

/ 06The 2026–2028 projection.

ISR randomisation will mature out of the top observation category as sponsors operationalise selection SOPs. Reagent-lot bridging will move into the top spot by 2028 — already trending. Combination-product DHF-to-BMV bridging, driven by QMSR effective 2 February 2026, will enter the top-5 by 2027 (covered separately in the QMSR note). Partial-validation pre-definition will persist as a category until SOPs cover the full change-category matrix. Method-transfer documentation will persist as long as transfers happen — with quality varying by the receiving laboratory's pre-transfer planning.

The mitigation for all four is the same: write the SOP that pre-specifies what will be done before the activity runs. Keep it under change control. Train against it. Run the activity to it. Document contemporaneously. The discipline is forty years old. The 2025 findings show that it is not yet ambient.